The Albanese Government has ensured thousands of Australians living with severe eczema will continue to have access to affordable treatments.
Dupixent is a highly effective treatment for severe eczema that's been on the PBS since 2021.
In July this year, higher than expected prescription numbers meant that patients were at risk of the dug sponsor, Sanofi, withdrawing Dupixent from the Pharmaceutical Benefits Scheme (PBS) - leaving thousands of patients without effective treatment and a bill of $20,000 per year.
The Government has reached an agreement with Sanofi and the Pharmaceutical Benefits Advisory Committee (PBAC) to secure the listing of Dupixent on the PBS, giving comfort to the almost 20,000 Australians living with severe eczema that they will continue to get access to this life changing treatment at affordable PBS prices.
Eczema is a long-lasting disease which causes dry, inflamed, and itchy skin. Patients with severe eczema have more frequent symptom flaring, and can suffer from itchy painful skin, bleeding, sleep deprivation, an increased risk of skin infections, depression and anxiety.
Dupixent, which reduces inflammation and provides relief, is available on the PBS for patients with severe eczema aged 12 years and older.
Instead of paying $20,000 per year, patients will pay a maximum of $31.60 per script, or just $7.70 if they hold a concession card.
Quotes attributable to Minister Butler:
"Since it was first listed on the PBS in 2021, Dupixent has improved the quality of life for thousands of Australians with severe eczema.
"The demand has been higher than expected, and we've worked hard to make sure that it remains affordable.
"I'm pleased we can continue to deliver cheaper medicines for the thousands of Australians living with severe eczema."
Eczema Support Australia, Managing Director Melanie Funk:
"Earlier this year, experts and advocates wrote to Minister Butler and Sanofi urging them to ensure Dupixent remained on the PBS for all Australians with severe and uncontrolled eczema.
"We are thrilled that a new agreement has been reached that allows so many Australians with this devastating disease to receive Dupixent through the PBS. Our Christmas really has come early.
"Dupixent has been life-changing for my twin boys and thousands of other Australians impacted by this debilitating, lifelong skin condition. Without this medicine, many lives would be unbearable.
"Today's announcement is a win for the eczema community and all Australians who care about affordable access to the best medicines. Thank you Minister."
